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Impaired adherence to medication regimens is a serious concern for individuals 
with schizophrenia linked to relapse and poorer outcomes.  One possible reason for 
poor adherence to medication is poor ability to remember future intentions, labeled 
prospective memory skills.  It has been demonstrated in several studies that 
individuals with schizophrenia have impairments in prospective memory that are 
linked to everyday life skills.  However, there have been no studies, to our 
knowledge, examining the relationship of prospective memory to medication 
management skills, a key element of successful adherence.  In this study 41 
individuals with schizophrenia and 25 healthy adults were administered a 
standardized test battery that included measures of prospective memory, 
medication management skills, neurocognition and symptoms.  Individuals with 
schizophrenia demonstrated impairments in prospective memory (both time and 
event-based) relative to healthy controls.  Performance on the test of prospective 
memory was correlated with the standardized measure of medication management 
in individuals with schizophrenia.  Moreover, the test of prospective memory 
predicted skills in medication adherence even after measures of neurocognition 
were accounted for.  This suggests that prospective memory may play a key role in 
medication management skills and thus should be a target of cognitive remediation 









  Prospective memory (PM) is defined as the ability to remember a task and 
perform it at an assigned time in the future (e.g., Shum et al., 2004).  For example, 
prospective memory is required to remember to attend a doctor’s appointment in the 
future or to take medication at an assigned time.  This process has been suggested to 
involve four stages (Shum et al. 2004).  The first is forming the intention to perform the 
task, second is remembering this formed intention over a period of time; third is 
continually remembering the time and method of executing the intention.  Finally, one 
must actually perform the intention and recall that it has been performed.   
 There has been increasing research interest in investigating PM impairments in 
people with schizophrenia (Altgassen et al., 2008; Elvevag et al., 2003; Henry, et al., 
2007; Kondel, 2002; Kumar et al., 2005; Kumer et al., 2008; Ritch et al., 2003; Shum et 
al., 2004; Twamley et al., 2007; Ungvari et al., 2008; Wang et al., 2007; Woods et al., 
2007).  A number of studies have used computerized laboratory tasks modeled after that 
of McDaniel and Einstein (2000) (e.g., Ungvari et al., 2008).  These laboratory based 
tasks all share important features including a delay between encoding and performance of 
the intended action, an ongoing task carried out during the delay, and no explicit 
reminder to perform the task when the cue appears.  Tasks can be time-based (requiring 
the individual to keep track of the time) or event-based (where an external cue indicates 
that it is time to perform the intended action).  Findings from these studies have 
demonstrated consistent impairments in PM in individuals with schizophrenia compared 





impairments appear to be greater for time-based tasks in some studies (Shum et al., 2004; 
Wang et al., 2009) others have not found a difference in performance on time-based tasks 
compared to event-based tasks (Henry et al., 2007; Woods et al., 2007). 
Consistent findings in schizophrenia include a relationship between PM and 
retrospective memory and executive function, among others neurocognitive skills (Kumar 
et al., 2008; Shum et al., 2004; Ungvari et al., 2008; Wang et al., 2008; Woods et al., 
2007), and severity of negative symptoms (Wang et al., 2009).  Notably, performance on 
PM tasks in schizophrenia, however, cannot be reduced to performance on tests of 
traditional neurocognitive domains such as general cognitive skill, retrospective memory 
and executive function (Henry et al., 2007). There has also been recent interest in the 
relationship between PM performance and everyday tasks or activities of daily living 
(ADL) (Ritch et al., 2003; Twamley et al. 2007; Ungvari et al., 2008; Zogg et al., 2010).  
Ritch et al. (2003) reported that the sum score of time- and event-based PM tasks 
predicted more than 29% of the variance of ADL scores.  Twamley et al. (2006) reported 
a positive relationship between a performance-based measure of ADLs  (UPSA-Brief) 
and the Memory for Intentions Screening Test (MIST).  Event-based prospective memory 
performance was the strongest predictor of everyday functioning.  In contrast, Ungvari et 
al. (2008) did not find a relationship between PM performance and ADLs using the 
Functional Needs Assessment-Chinese Version.  Discrepancies between studies may be 
linked to differences in aspects of daily functioning assessed, such as cognitive difficulty 
or automaticity: some everyday life tasks, such as appropriate grooming, would seem to 
be less dependent upon prospective memory skills than others, such as remembering a 





One important daily activity that relies on PM is, of course, medication adherence.   
Individuals with schizophrenia have been shown to perform poorly on performance-based 
measures of medication management (Kurtz, et al., 2007).  For example, Patterson and 
colleagues used the Medication Management Ability Assessment (MMAA) to test the 
medication management abilities of 104 older (over age 40) adults with schizophrenia 
(Patterson et al., 2002). This test consists of a doctor-patient role-play in which the 
subject is required to repeat a daily regime of medication.  It was found that individuals 
with schizophrenia made significantly more errors in the task than normal controls.  
Construct validity for this task was supported by prescription refill records, relationship 
to performance-based measures of everyday functioning and self-reported quality of life.  
Those individuals that had more severe psychiatric symptoms performed worse than 
those with less severe symptoms, and those individuals that were older performed worse 
than those that were younger.  Interestingly, performance on the MMAA correlated with 
performance on an overall measure of cognitive function.    
Using a cognitive screening measure Jeste et al. (2003) evaluated the relationship 
between medication adherence and cognitive functioning in a sample of 104 outpatients 
with schizophrenia or schizoaffective disorder. These authors reported that level of 
cognitive functioning predicted ability to manage medications, with measures of 
retrospective memory and conceptualization most closely linked to medication 
management abilities.   
Despite replicated findings that medication management skills are impaired in 
schizophrenia, reflect (at least in part) deficits in cognition, and that prospective memory 





knowledge, medication management skills has not been studied specifically in 
relationship to PM performance, and other illness features in individuals with 
schizophrenia.   
 In this study we used the MIST as an assessment of PM.  The MIST is one of only 
a few standardized clinical measures of PM (Raskin, Buckheit & Sherrod, 2011).  The 
MIST has the advantage of having been shown to have good psychometric properties 
(Raskin, 2009; Woods et al., 2008), but to still allow for the analysis of various 
underlying causes for the PM failure.  Thus, the MIST allows for the comparison of long 
and short delay times, event-based and time-based cues, and verbal and action responses 
across balanced trials.  We compared performance on the various aspects of the MIST to 
a standardized measure of medication adherence, the MMAA, and performance on 
measures of attention, working memory, and executive-function. First, we predicted that 
prospective memory skills would be worse in individuals with schizophrenia compared to 
demographically matched healthy adults and that time- and event-based prospective 
memory would be equivalently impaired in individuals with schizophrenia relative to 
demographically matched healthy adults.  Second, in those with schizophrenia, we 
predicted that prospective memory skills, measures of attention, learning and set-shifting 
would be linked to medication management skills.  Third, in those with schizophrenia we 
predicted that prospective memory skills would explain variance in medication 







Forty-one individuals, (18 female), from the Schizophrenia Rehabilitation 
Program (SRP) at the Institute of Living at Hartford Hospital in Hartford, CT (n=37) and 
Intercommunity Mental Health Center in East Hartford, CT (n=4) participated. Twenty-
five matched healthy adult individuals (12 female) were also tested.    
Individuals with schizophrenia met criteria for schizophrenia or schizoaffective 
diagnosis as described in the DSM-IV (American Psychiatric Society, 2000) via the 
Structured Clinical Interview for the DSM-IV (SCID; First et al., 1995). Each patient also 
met inclusion criteria of sufficient hearing and visual abilities, completion of a minimum 
of eight years of schooling, and fluency in English.  Exclusion criteria required that the 
patient be free from any current alcohol or substance abuse, mental retardation as 
evidenced by a history of services, or other neurologic or psychiatric illness, as well as 
current treatment with electroconvulsive therapy. The Positive and Negative Syndrome 
Scale (PANSS) scores were obtained to determine frequency and intensity of positive and 
negative symptoms associated with schizophrenia at the time of the study (Kay, Fiszbein, 
& Opler, 1987). Exclusion criteria for the healthy adults included auditory or visual 
impairments, evidence of mental retardation, traumatic brain injury with a sustained loss 
of consciousness, presence or history of any neurologic or psychiatric illness, lack of 
proficiency in English or history of substance abuse or dependence. Demographic data 
for individuals with schizophrenia and matched controls are presented in 1. There were 
no significant differences between the groups in terms of age, gender or education.  The 






 The Medication Management Ability Assessment Manual (MMAA; Patterson et al. 
2002):.  This test involved a doctor-patient role play in which the patient was asked to 
remember a regime of medication similar to one required in a typical day.  Detailed 
instructions were given to the participant explaining how to take the medication.  The 
dosage required, time of day and whether it required food was explained.  The participant 
was also shown the pill bottles that described the information that had just been explained.   
After a delay of 45-60 minutes (during which other tests were administered) the 
participants were asked to explain what time they would wake up, when they would eat 
meals, and when they would go to sleep, explaining when they would take their 
medications relative to these events throughout the day.  Four mock medications were 
included in this test; each represented with a different type of uncooked bean to simulate 
different pills.  The test was then scored based on the number of pills taken each time, the 
number of times per day the pill was taken, and the total number of pills taken per day. A 
total correct score was selected for analysis this this study.   
Memory for Intentions Screening Test (MIST; Raskin, Buckheit, & Sherrod, 2011).  
This was a prospective memory test that used both event-based and time-based cues to 
assess the participant’s ability to remember tasks and carry them out.  There were a total 
of eight tasks which the participant was required to remember to perform at an assigned 
time or when a specific cue was given.  An example of an event-based cue was “when I 
hand you an envelope, self-address it.”  An example of a time cue was “in fifteen minutes, 
please tell me to take a break.”  The participant had access to a digital clock throughout 





task that was a word search puzzle.  They were not permitted to write any information 
down.   
Finally, a battery of standardized neuropsychological measures was administered 
chosen a priori to tap into underlying cognitive processes required for PM performance.  
The tests used included measures of attention Trail Making Test A [TMT, Tombaugh, 
2004]), learning and memory(California Verbal Learning Test-II-CVLT, Delis, Kramer, 
Kaplan, & Ober, 2012]) and set-shifting (Trail Making Test B [TMT, Tombaugh, 2004]).  
Procedure 
Total testing lasted approximately one hour and fifteen minutes.  All participants 
gave written, informed consent and all procedures met institutional ethical approval.  
When testing began, the first part of the MMAA was initially administered. During the 
interim period, the MIST and the neuropsychological measures were administered 
followed by the second, testing phase of the MMAA. 
Data Analysis  
None of the MIST measures were normally distributed as revealed by a series of 
Shapiro-Wilk W tests (all ps<.01). Thus a series of non-parametric tests and Cohen’s d 
(Hedges and Olkin, 1985) values were used to compare healthy control and patient 
samples on variables from the MIST. In all cases reported ANOVA results on raw study 
data were confirmed with rank-transformed data; in no case was there a discrepancy in 
findings. Spearman rank-order correlations were calculated within the schizophrenia 
group to assess the relationship of the MIST scores and other neurocognitive variables, 
illness and demographic factors and medication management skills as measured by the 





medication management skills was selected in order to evaluate the relative contribution 
of neurocognitive and the MIST summary score to MMAA scores in a logistic regression 
analysis. Alpha was set at .05 and all analyses were two-tailed.  
RESULTS 
 
As can be seen in Table 2 individuals with schizophrenia performed significantly 
more poorly than healthy adults on the MIST summary score (d=-.88), on responses to 
time- (d=-.84) and event (d=-.67) based cues, and on 15-minute (d=-1.02) but not 2-
minute delayed responses, and on action (d=-1.09) but not verbal responses. Recognition 
(d=-.54) performance and 24-hr (d=-.69) delay performance was impaired on the MIST 
in the schizophrenia sample relative to healthy controls.  There was no significant 
difference in discrepancy between groups for the time and event-based cue responses 
(p=.22) or action and verbal responses (p>.05). There was greater impairment on the long 
as compared to short-delay items relative to healthy control performance (Group x Delay 
interaction, [F(1, 64)=5.02, p=.021]).  For error type, only the no response error type was 
more common in individuals with schizophrenia (d=-.72). No response errors were 
selectively more common in individuals with schizophrenia as compared to controls 
relative to the other four error types as indicated by a group x error type interaction (F(4, 
256)=5.09 p=.001).  
Spearman rank-order correlations were conducted between clinical and 
demographic variables, neurocognitive variables, MIST variables and the MMAA in the 
schizophrenia sample (Table 3).  CVLT-II T-scores (rho=.37), and Trails B time (rho=-
.30) and Summary scores (rho=.45) from the MIST were all related to MMAA scores. 





cued (rho=.55**) responses, and responses that required an action (rho=.61**) rather 
than a verbal statement  were most closely linked to MMAA scores.   
A forward stepwise logistic regression analysis was conducted to predict a 
person’s ability to remember to take their medication using variables found to be 
signficant in the correlational analysis: the summary score of prospective memory ability 
from the MIST, the CVLT-II and Trails B. A binary variable was created for the MMAA 
with a cutoff of 20 (80% accuracy). Neuropsychological variables were entered in block 
one and summary score from the MIST was entered in block two. A test of the full model 
against a constant only model was statistically significant, indicating that the predictors 
as a set reliably distinguished between individuals having a total MMAA of less than 21 
with those having a higher score (between 21 and 25) (chi square = 6.31, p =0.012 with 
df =1). Prediction success overall was 73%. The Wald criterion demonstrated that Total 
on the MIST made a significant contribution to prediction (p =.048). The remaining 
tested variables were not significant predictors.  
DISCUSSION 
A growing body of research has documented deficits in prospective memory in 
schizophrenia relative to demographically-matched, healthy adults. The current study was 
designed to build on this work by both replicating previous findings in samples of healthy 
adults and people with schizophrenia, and then investigating the relationship of impaired 
prospective memory skills, commonly measured cognitive skills and symptoms to 
performance-based medication adherence skills in individuals with schizophrenia. This 
study is among the very first studies in the literature to investigate this relationship. 





2007; Elvevag et al., 2003), our results showed that prospective memory in schizophrenia 
was impaired relative to demographically matched healthy adultperformance with effect-
size impairment in the large range (d=.88 for the MIST summary score) which was 
remarkably consistent with previous reports.  Consistent with previous reports using an 
identical index of prospective memory (Woods et al., 2007) there was no evidence that 
responses to time-based prospective memory cues were more impaired than responses to 
event-based cues.  These findings provide more data that differences between 
performance on time and event-based prospective tasks in previous studies (e.g., Shum et 
al., 2004) may reflect the confounding of these conditions with the complexity of cue-
intention pairings which are carefully matched for difficulty across time and event-based 
tasks on the MIST.   
An analysis of error type revealed a selective deficit in no response (PM) errors as 
compared to healthy controls, relative to the frequency other error types. These errors 
reflect the participant giving no indication that there is an intention to be carried out.  
These findings suggest that when prospective memory performance skills break down in 
individuals with schizophrenia this most commonly reflects a failure to attend to or react 
to the prospective memory cues on the MIST.  However, our findings also indicate that 
even when individuals with schizophrenia were able to detect a cue they more frequently 
made incorrect responses as compared to healthy controls, suggesting evidence of either 
poorly formed representations of cue-response pairings or problems with response 
retrieval even when the cue was accurately recognized.  
Analysis of our recognition results did not support the contention reported in two 





adequately formed cue-intention relationships can be detected in individuals with 
schizophrenia when strategic retrieval processes are minimized in the context of a 
recognition test format, although differences in recognition effect-size results between 
our study and previous studies were not large (d=.54 in the current study vs. d=.32 in the 
Woods et al. study), and may reflect slight differences in recognition scoring procedures. 
These findings coupled with our result that errors in response at a 15-minute delay 
(d=1.02) were twice as large as those at a 2-minute delay (d=.50) suggest that prospective 
memory skills may not conform to the common characteristics of retrospective memory 
impairment in schizophrenia in which encoding and retrieval processes are impaired but 
consolidation and maintenance processes remain largely intact (Aleman et al., 1999).  
With respect to our second hypothesis, measures of set-shifting (Trails B), verbal 
learning (CVLT-II) (but not visual attention [Trails A]) and prospective memory skills 
were related to medication management skills (MMAA). These findings are consistent 
with previous work investigating the relationship of summary cognitive screening 
measures and medication management skills (e.g., Jeste et al. 2003) and extend these 
findings to two key and specific cognitive function domains in schizophrenia. These 
findings are also remarkably consistent with the reported relationship of prospective 
memory skills to measures of ADL functional capacity in schizophrenia (Twamley et al., 
2008) and suggest similar magnitude relationships of prospective memory with the 
specific skills of remembering to take a sequence of medications in the correct amount at 
the correct times. The finding that errors for event cues were more closely related to 





monitoring and self-initiated retrieval demands would seem greater for time-based cues 
and thus would be more likely to be linked to medication management skills.  
With respect to hypothesis three, results of binary logistic regression predicting 
the adherence to a mock medication regimen, (defined as the likelihood of attaining 80% 
accuracy on the medication management skill tests), showed that prospective memory 
skills explained variance in adherence measures even after accounting for cognitive 
measures supporting the potential incremental clinical utility of including prospective 
memory measures for predicting medication management skills in schizophrenia.  
  Several limitations to the current study should be noted. First, study sample sizes 
were modest and significant relationships may have been overlooked secondary to 
limited power. Second, lack of adherence with prescribed medications involves a 
complex interplay of cognitive and attitudinal factors including illness insight. The 
medication management skill measure employed in the current study modeled cognitive 
skills necessary for taking a complex regimen of medications, a necessary but not 
sufficient skill for medication adherence. We note however that a paper published very 
recently extends these findings to medication refill records (Lam et al., 2013). Third, the 
neuropsychological test battery employed in the current study was limited in scope, 
capturing only a few of the separable neurocognitive domains defined in factor analyses 
using broad spectrum neurocognitive assessment batteries in schizophrenia.  
 In summary, the current results suggest that prospective memory is impaired in 
schizophrenia relative to demographically matched controls, deficits are of equivalent 
magnitude for time and event-based cues and this impairment is driven largely by failures 





patients, both prospective memory measures and cognitive skills in set-shifting and 
verbal learning predicted performance on a performance-based measure of medication 
management skills. Importantly, prospective memory skills explained variance in 
medication management skills beyond that of standardized neurocognitive measures. 
These findings provide a rationale for the development of remediation strategies that 
facilitate the encoding of cue-response relationships (perhaps with extended encoding 
time or practice), and then provide environmental modifications that both increase the 
salience of cues and tie these cues more directly to the target response as a means of 
addressing the cognitive disabilities that interfere with medication adherence in 
schizophrenia (e.g., Raskin & Sohlberg, 2011).  
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Table 1: Demographic and disease information for individuals with schizophrenia and 
healthy adults 
  HA (n = 24)   SCZ (n = 41)   
  Mean 
Std. 
Deviation   Mean 
Std. 
Deviation t 
Age 43.44 23.13 
 
44.17 10.74 0.174 (NS) 
Gender (% male) 52 - 
 
56 - 
 Education(years) 13.92 2.23 
 
12.37 2.54 -2.52 (NS) 
Occupation* 7.2 0.58 
 
7.10 0.81 -0.49 (NS) 
Maximum Lifetime Duration of 
Employment (months) n/a n/a 
 
30.19 45.13 - 
Lifetime Hospitalizations n/a n/a 
 
3.78 2.84 - 
Duration of Illness (years) n/a n/a 
 
12.50 9.9 - 
PANSS 
      Total Positive n/a n/a 
 
15.05 5.57 - 
Total Negative n/a n/a 
 
17.35 6.99 - 
Total General n/a n/a 
 
34.59 9.89 - 
Total PANSS n/a n/a  71.45 14.49  - 
*Hollingshead (1977) 
      Note: HA = healthy adult; SCZ = schizophrenia; NS = not significant; n/a = not applicable; 







Table 2: Prospective Memory and Medication Management Ability in the Study Samples   
 
HA (n = 25) 
 
SCZ (n = 41) 
 
  




ES (95% CI ) 
MIST 
      
  
Summary score (of 48) 40.28 7.78 
 
31.88 10.23 3.44** -.88 (-1.40/-.36) 
Time (of 8) 5.96 2.03 
 
4.37 2.01 2.97** -0.84 (-1.36/-0.33) 
Event (of 8) 7.40 0.91 
 
6.39 1.75 2.41* -0.67 (-1.18/-0.16) 
2-min (of 8) 7.48 0.96 
 
6.63 1.97 1.74 -0.50 (-1.01/0) 
15-min (of 8) 6.08 1.78 
 
4.15 1.93   3.69**  -1.02 ( -1.54/-.49) 
Verbal (of 8) 6.52 1.83 
 
5.76 2.13 1.69 -.37 (-.87/-.13) 
Action (of 8) 6.76 1.36 
 
5.07 1.62 3.87**  -1.09 (-1.62/-.56) 
Recognition (of 8) 7.56 0.87 
 
7.00 1.12 2.24* -.54 (-1.09/-.03) 
    24-hr (of 2) 1.17 1.01  0.54 0.84 2.49** -.69 (-1.20/-.17) 
Errors 
       
NR 0.65 1.04 
 
2.02 2.21 3.02** -.72 (-1.24/-.22) 
TS 0.32 0.48 
 
0.71 0.95 1.73 -.48 (-.9/.02) 
LC 0.44 0.58 
 
0.54 0.71 .36 -.15 (-.65/.35) 
LT 0.24 0.44 
 
0.34 0.57 0.56 -.19 (-.69/.31) 
PLO 0.00 0.00 
 
0.02 0.16 0.78 -.16 (-.65/.34) 
MMAA 
       
Total 22.72 2.56 
 
17.00 6.56 3.58** -1.04 (-1.57/-.52) 
        
        
Note: *p<.05; **p<.01; ***p<.001; HA = healthy adult; SCZ = schizophrenia; MIST = Memory for Intentions Screening Test; 
MMAA = Medication Management Ability Assessment; NR = no response error; TS = task substitution error; LC = loss of content 





Table 3: Spearman correlations for individuals with 
schizophrenia between neurocognitive, MIST and 
MMMA variables (n=41) 
  MMAA Total 
Demographic and Clinical Variables 
 Age -0.26 
Education 0.31 
Duration of Illness -0.08 
Positive Symptoms -0.23 
Negative Symptoms -0.18 
MIST Variables 
 MIST Summary 0.45** 
Time Cue .33* 
Event Cue .55** 
Verbal Response .13 
Action Response .61** 
2-minute Delay .29 
15-minute Delay .44 
Neuropsychological Measures 
 TMT-A 0.14 
CVLT-II 0.37** 
TMT-B -0.30** 
Note: *p<.05; **p<.01;; TMT= Trail Making Test; 
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